Point-of-care molecular diagnostics market seen reaching $7.91 billion by 2030

The point-of-care molecular diagnostics market is projected to grow from $3.98 billion in 2025 to $7.91 billion by 2030, driven by infectious disease testing, faster clinical decisions and broader use in hospitals and home settings. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Point-of-care molecular diagnostics help clinicians identify infections and other diseases quickly, which can speed treatment decisions in urgent care and hospital settings. - The market’s growth reflects rising demand for faster testing as infectious and respiratory illnesses remain a major health burden. - The category is also expanding into home-based testing, respiratory care and oncology, widening its commercial reach.

What happened: - The point-of-care molecular diagnostics market was valued at $3.98 billion in 2025. - The market is projected to reach $4.58 billion in 2026, implying 15.0% annual growth. - The market is forecast to climb to $7.91 billion by 2030, at a 14.7% CAGR. - The Business Research Company released the market study on Aug. 24, 2026. - A free sample of the report is available here.

The details: - Point-of-care molecular diagnostics identifies specific DNA or RNA in clinical samples such as feces, saliva, urine, blood and tissue. - The tests are used to detect microbial genetic material and support rapid disease identification. - The report says point-of-care molecular diagnostics are widely used in healthcare settings for emergency use authorization purposes. - The testing category is used to identify disease antigens or antibodies in human samples. - Common applications include detection of mononucleosis, influenza and group A streptococcus. - Historic growth has been supported by more infectious disease cases, broader use of emergency diagnostic testing, faster clinical decision-making, better molecular assay technology and wider hospital adoption. - Future growth is expected to come from home-based molecular testing, rapid diagnostic infrastructure investment, respiratory and oncology testing expansion, cloud-based diagnostic platforms and earlier disease detection. - North America held the largest regional market share in 2025. - Asia-Pacific is projected to be the fastest-growing regional market during the forecast period. - The regional analysis also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and future trend analysis.

Between the lines: - The forecast suggests point-of-care molecular diagnostics is moving from a niche clinical tool to a broader testing platform across more care settings. - The focus on home testing and cloud-based platforms points to a market that is becoming more distributed and digitally connected. - The report’s regional split suggests the largest opportunities may be mature in North America, while growth momentum shifts toward Asia-Pacific. - UK data cited in the release showed 1,681 critical care admissions for confirmed influenza across 108 NHS trusts in England between week 40 of 2022 and week 15 of 2023, compared with 182 admissions across 114 trusts in the previous season and 316 by week 39 of 2022.

What's next: - The market is expected to keep expanding through 2030 as rapid testing demand rises across hospitals, emergency care and home settings. - Wider adoption of respiratory and oncology applications could broaden demand beyond infectious disease testing. - Continued investment in diagnostic infrastructure and digital platforms could shape competitive positioning over the next several years. - A full report is available here.

The bottom line: - Point-of-care molecular diagnostics is on track for sustained double-digit growth, with faster testing needs and expanding use cases driving the market toward $7.91 billion by 2030.